CN102349912A - Medicament for preventing and treating radioactive skin injury - Google Patents
Medicament for preventing and treating radioactive skin injury Download PDFInfo
- Publication number
- CN102349912A CN102349912A CN2011102561261A CN201110256126A CN102349912A CN 102349912 A CN102349912 A CN 102349912A CN 2011102561261 A CN2011102561261 A CN 2011102561261A CN 201110256126 A CN201110256126 A CN 201110256126A CN 102349912 A CN102349912 A CN 102349912A
- Authority
- CN
- China
- Prior art keywords
- content
- medicine
- skin injury
- ectoin
- injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention aims to provide a medicament for effectively preventing and treating radioactive skin injury. The medicament comprises 0.5 to 10 weight percent of ectoin, 0.5 to 10 weight percent of hydroxy ectoin and the balance of water. The ectoin and the hydroxy ectoin can resist the injury effect of rays such as ultraviolet and the like on the skin, and have the following mechanisms that: (1) a protective layer formed on the surface of cells resists the injury of the rays; (2) by protection of protein and nucleic acid and action of denaturation prevention, intercellular protein denaturation caused by ray radiation and duplication disorder and error of double helix structures due to injury of DNA are prevented, and cancerization is prevented; (3) repair of injured protein or nucleic acid is assisted; and (4) the ectoin is combined with water molecules to form a water film for moisturizing, and a physiological wet environment is formed on the wound surface, so that value is increased and growth of granulation tissues is promoted. Therefore, the medicament using the ectoin or the hydroxy ectoin as a main effective ingredient can effectively prevent and treat the radioactive skin injury.
Description
Technical field
The present invention relates to the medicine of a kind of prevention and treatment skin injury, the medicine of especially a kind of prevention and radiotherapy property skin injury.
Background technology
Radiation skin injury mainly is meant skin, the subcutaneous tissue that causes owing to irradiation skins such as X, β and gamma-rays, even bone damage.The patient has plenty of the radiation work practitioner, has plenty of radiocurable patient.
The Hopewell report, the time that skin reacts and begins after the radiation: 1. dry 3～6 weeks of decortication; 2. 4～6 weeks of ulcer; 3. ulcer＞6 weeks repeatedly; 4. corium necrosis＞10 weeks; 5. dermal atrophy＞6 weeks; 6. telangiectasis＞52 weeks; 7. soaking into fibrosis forms relevant with the scar tissue that mode of healing, acute ulcer, recurrence ulcer and corium necrosis cause; 8. acute ulcer＜14d; Acute epidermis necrosis＜10d.
The mechanism of curing dermal radio lesions mainly is the germinal layer cell of epithelium and the variation of veins beneath the skin.At first see at irradiated site blood capillary reflex dilatation, erythema appears in the congested reaction of local formation, and blood vessel injury and microcirculation disturbance take place, and forms ulcer then.And the reason that causes poor wound healing is progressive blood capillary obstruction, and epithelial cell and fibroblast proliferation are bad.Especially radiation causes the damage of DNA in the cell, causes double-stranded disorder and the mistake of duplicating, and is the basis of causing canceration, and the canceration incidence rate of radiodermatitis is 20%～30%.
The classification radiation skin injury of radiation skin injury can be divided into acute radiation skin injury and chronic radioactive skin injury again.The clinical manifestation acute radiation skin injury of acute radiation skin injury, generally be divided into 1. initial reaction phase 4 phases: patient's skin, mucosa are not found changes such as tangible pachylosis, hair follicle pimple, erythema.2. incubation period: I ° of skin injury 10～65d, average 28d.II ° of skin injury 8～34d, average 21d.3. fundamental reaction phase: initial skin has the sense of expanding, pruritus, back pachylosis, or the big or small hair follicle pimple of foxtail millet grain appears being dispersed in.Or the initial stage be speckle, patch shape erythema enlarges gradually, merges, color and luster deepens to be mulberry, that presses does not fade.The vesicle of different in kind appears in 7～16d after the erythema, shallow erosion of local table or formation ulcer behind the ulceration.4. convalescent period: get into after convalescent period, I ° of skin injury begins desquamation, and pigmentation does not have obvious subjective symptoms.After the shallow II ° of skin ulcer emaciated face crust, pigmentation, no cicatrization.Depigmentation after the dark II ° of healing forms graniphyric.
The clinical manifestation chronic radioactive skin injury of chronic radioactive skin injury has long incubation period, and the state of an illness has characteristics such as tangible potentiality, carrying out property, repeatability and persistence.Clinical manifestation can be divided into 4 types of chronic radiodermatitis, edema indurativum, chronic radiation ulcer and radioactive skin cancers, and is wherein common with radiodermatitis.
Summary of the invention
The medicine that the purpose of this invention is to provide a kind of effective prevention and radiotherapy property skin injury, and can effectively prevent canceration.
Realize a kind of prevention of the object of the invention and the medicine of radiotherapy property skin injury, comprise tetrahydropyrimidine and hydroxy tetrahydro pyrimidine, content is 0.5wt%～10wt%, water surplus.
The medicine of described prevention and radiotherapy property skin injury is cream or ointment medicament, also comprises thickening Emulsion, emulsifying agent, polysorbate60, olive oil and ethyl hydroxybenzoate.
The content of said polysorbate60 is 0.1wt%～1wt%; The content of said olive oil is 0.5wt%～2wt%; The content of said ethyl hydroxybenzoate is 0.1wt%～0.2wt%.
Described thickening agent comprises one or more mixture in octadecanol, hexadecanol, Cera Flava, the pure and mild lanoline of octacosane.
The content of said octadecanol is 2wt%～15wt%; The content of said hexadecanol is 1wt%～10wt%; Said mellisic content is 5wt%～20wt%; The content of said octacosanol is 5wt%～20wt%; The content of said lanoline is 2wt%～20wt%, and above-mentioned content is the medicine total content.
Said emulsifying agent comprises glycerol and/or polyol fatty acid ester.
The content of said glycerol is 1wt%～5wt%; The content of said polyol fatty acid ester is 0.1wt%～2wt%.
The medicine of described prevention and radiotherapy property skin injury is a spray, also comprises antibacterial and aromatic radical.
The content of said antibacterial is 0.05wt%～0.1wt%; The content of said aromatic is 0.01wt%～0.2wt%.
Said antibacterial is a benzalkonium chloride; Said aromatic is phenethanol.
The beneficial effect of the medicine of a kind of prevention of the present invention and radiotherapy property skin injury is following:
Because tetrahydropyrimidine and hydroxy tetrahydro pyrimidine can be resisted the damaging action of ray such as ultraviolet to skin; Its mechanism comprises that (1) cell surface forms the damage that protective layer is resisted ray; (2) prevent that through effect intracellular protein degeneration that x radiation x causes and the damage of DNA from causing double-stranded disorder and the mistake of duplicating, and prevents canceration to the protection of albumen, nucleic acid and anti-degeneration.(3) assist impaired albumen or nucleic acid reparation.(4) the tetrahydropyrimidine bound water molecule forms moisture film and plays moisture-keeping function, on wound surface, forms the physiological moist environment, and growth with granulation tissue helps rising in value.Therefore, medicine of the present invention as main effective ingredient, can effectively prevent tetrahydropyrimidine or hydroxy tetrahydro pyrimidine and radiotherapy property skin injury.
The specific embodiment
Embodiment 1 (cream)
The composition and the content thereof of the cream medicine of the prevention of present embodiment and radiotherapy property skin injury are following:
| Octacosanol | 10g |
| Octadecanol | 6g |
| Hexadecanol | 3g |
| Tween-60 | 0.5g |
| Lanoline | 6g |
| Olive oil | 1g |
| Glycerol | 5g |
| Tetrahydropyrimidine | 3g |
| The hydroxy tetrahydro pyrimidine | 3g |
| Methyl hydroxybenzoate | 0.2g |
| Purify waste water | 62.3ml |
The therapeutic effect of the medicament of present embodiment is following:
The curative effect determinate standard recovery from illness: wound surface heals fully; Incrustation also comes off. and produce effects: wound surface obviously dwindles; Healing area＞50%; No secretions; The granulation tissue normal growth. effectively: wound surface does not have expansion; Healing area 20%～50%, exudate reduces. and invalid: wound surface no change or expansion. total effective rate=(recovery from illness+produce effects)/total routine number; Healing rate=recovery from illness/total routine number.
Can see that in 40 patients' altogether clinical research the composition of medicine that contains 3% tetrahydropyrimidine and 3% hydroxy tetrahydro pyrimidine in utilization is after 1 week of treatment, 28 recoveries from illness, 8 produce effects, 4 are effectively.
Total effective rate is 90%, and healing rate is 70%.
Embodiment 2 (cream)
The composition and the content thereof of the cream medicine of the prevention of present embodiment and radiotherapy property skin injury are following:
| Octacosanol | 20g |
| Cera Flava | 10g |
| Hexadecanol | 1g |
| Tween-60 | 0.1g |
| Lanoline | 2g |
| Olive oil | 0.5g |
| Glycerol | 1g |
| Tetrahydropyrimidine | 10g |
| The hydroxy tetrahydro pyrimidine | 10g |
| Methyl hydroxybenzoate | 0.1g |
| Purify waste water | 45.3ml |
The therapeutic effect of the medicament of present embodiment is following:
Curative effect determinate standard is the same.
Can see that in 40 patients' altogether clinical research the composition of medicine that contains 5% tetrahydropyrimidine and 5% hydroxy tetrahydro pyrimidine in utilization is after 1 week of treatment, 30 recoveries from illness, 8 produce effects, 2 are effectively.
Total effective rate is 95%, and healing rate is 75%.
Embodiment 3 (cream)
The composition and the content thereof of the cream medicine of the prevention of present embodiment and radiotherapy property skin injury are following:
| Octacosanol | 5g |
| Octadecanol | 15g |
| Hexadecanol | 10g |
| Tween-60 | 1g |
| Lanoline | 20g |
| Olive oil | 2g |
| Glycerol | 3g |
| Tetrahydropyrimidine | 0.5g |
| The hydroxy tetrahydro pyrimidine | 0.5g |
| Methyl hydroxybenzoate | 0.2g |
| Purify waste water | 41.8ml |
The therapeutic effect of the medicament of present embodiment is following:
Curative effect determinate standard is the same.
Can see that in 30 patients' altogether clinical research the composition of medicine that contains 10% tetrahydropyrimidine and 2% hydroxy tetrahydro pyrimidine in utilization is after 1 week of treatment, 24 recoveries from illness, 4 produce effects, 2 are effectively.
Total effective rate is 93%, and healing rate is 80%.
Embodiment 4 (spray)
The composition and the content thereof of the medicine spray of the prevention of present embodiment and radiotherapy property skin injury are following:
| Tetrahydropyrimidine | 3g |
| Benzalkonium chloride | 0.1g |
| The hydroxy tetrahydro pyrimidine | 3g |
| Phenethanol | 0.2ml |
| Purify waste water | 93.7ml |
The therapeutic effect of the medicament of present embodiment is following:
Curative effect determinate standard is the same.
Can see that in 40 patients' altogether clinical research the composition of medicine that contains 3% tetrahydropyrimidine and 3% hydroxy tetrahydro pyrimidine in utilization is after 1 week of treatment, 28 recoveries from illness, 8 produce effects, 4 are effectively.
Total effective rate is 90%, and healing rate is 70%.
Embodiment 5 (spray)
The composition and the content thereof of the medicine spray of the prevention of present embodiment and radiotherapy property skin injury are following:
| Tetrahydropyrimidine | 0.5g |
| Benzalkonium chloride | 0.1g |
| The hydroxy tetrahydro pyrimidine | 8g |
| Phenethanol | 0.1ml |
| Purify waste water | 91.3ml |
The therapeutic effect of the medicament of present embodiment is following:
Curative effect determinate standard is the same.
Can see that in 20 patients' altogether clinical research the composition of medicine that contains 3% tetrahydropyrimidine and 10% hydroxy tetrahydro pyrimidine in utilization is after 1 week of treatment, 18 recoveries from illness, 1 produce effects, 1 is effectively.
Total effective rate is 95%, and healing rate is 90%.
Embodiment 6 (spray)
The composition and the content thereof of the medicine spray of the prevention of present embodiment and radiotherapy property skin injury are following:
| Tetrahydropyrimidine | 8g |
| Benzalkonium chloride | 0.1g |
| The hydroxy tetrahydro pyrimidine | 0.5g |
| Phenethanol | 0.2ml |
| Purify waste water | 91.2ml |
The therapeutic effect of the medicament of present embodiment is following:
Curative effect determinate standard is the same.
Can see that in 20 patients' altogether clinical research the composition of medicine that contains 10% tetrahydropyrimidine and 1% hydroxy tetrahydro pyrimidine in utilization is after 1 week of treatment, 18 recoveries from illness, 2 produce effects.
Total effective rate is 100%, and healing rate is 90%.
Claims (10)
1. the medicine of prevention and radiotherapy property skin injury comprises tetrahydropyrimidine and hydroxy tetrahydro pyrimidine, and content is 0.5wt%～10wt%, water surplus.
2. the medicine of prevention according to claim 1 and radiotherapy property skin injury; It is characterized in that: the medicine of said prevention and radiotherapy property skin injury is cream or ointment medicament, also comprises thickening Emulsion, emulsifying agent, polysorbate60, olive oil and ethyl hydroxybenzoate.
3. the medicine of prevention according to claim 2 and radiotherapy property skin injury is characterized in that: the content of said polysorbate60 is 0.1wt%～1wt%; The content of said olive oil is 0.5wt%～2wt%; The content of said ethyl hydroxybenzoate is 0.1wt%～0.2wt%.
4. according to the medicine of claim 2 or 3 described preventions and radiotherapy property skin injury, it is characterized in that: described thickening agent comprises one or more mixture in octadecanol, hexadecanol, Cera Flava, the pure and mild lanoline of octacosane.
5. the medicine of prevention according to claim 4 and radiotherapy property skin injury is characterized in that: the content of said octadecanol is 2wt%～15wt%; The content of said hexadecanol is 1wt%～10wt%; Said mellisic content is 5wt%～20wt%; The content of said octacosanol is 5wt%～20wt%; The content of said lanoline is 2wt%～20wt%; Above-mentioned content is medicine total content proportion.
6. according to the medicine of claim 2 or 3 described preventions and radiotherapy property skin injury, it is characterized in that: said emulsifying agent comprises glycerol and/or polyol fatty acid ester.
7. the medicine of prevention according to claim 6 and radiotherapy property skin injury is characterized in that: the content of said glycerol is 1wt%～5wt%; The content of said polyol fatty acid ester is 0.1wt%～2wt%.
8. the medicine of prevention according to claim 1 and radiotherapy property skin injury is characterized in that: the medicine of said prevention and radiotherapy property skin injury is a spray, also comprises antibacterial and aromatic.
9. the medicine of prevention according to claim 8 and radiotherapy property skin injury is characterized in that: the content of said antibacterial is 0.05wt%～0.1wt%; The content of said aromatic is 0.01wt%～0.2wt%.
10. the medicine of prevention according to claim 9 and radiotherapy property skin injury is characterized in that: said antibacterial is a benzalkonium chloride; Said aromatic is phenethanol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102561261A CN102349912A (en) | 2011-09-01 | 2011-09-01 | Medicament for preventing and treating radioactive skin injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102561261A CN102349912A (en) | 2011-09-01 | 2011-09-01 | Medicament for preventing and treating radioactive skin injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102349912A true CN102349912A (en) | 2012-02-15 |
Family
ID=45573630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102561261A Pending CN102349912A (en) | 2011-09-01 | 2011-09-01 | Medicament for preventing and treating radioactive skin injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102349912A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104273131A (en) * | 2013-07-01 | 2015-01-14 | 镇江拜因诺生物科技有限公司 | Melon and fruit yield increasing agent |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030114358A1 (en) * | 2000-02-14 | 2003-06-19 | Erwin Galinski | Use of compatible solutes as inhibitors of the enzymatic decomposition of macromolecular biopolymers |
| DE102004016129A1 (en) * | 2004-03-31 | 2005-10-20 | Bitop Ag | Use of combination of osmolyte from extremophilic microorganism, e.g. (hydroxy)ectoine, and evening primrose oil in cosmetics, topical formulations, medical products and pharmaceuticals for skin care and prophylaxis |
| CN101011335A (en) * | 2006-02-03 | 2007-08-08 | Lvmh研究公司 | Protecting, regenerating composition |
-
2011
- 2011-09-01 CN CN2011102561261A patent/CN102349912A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030114358A1 (en) * | 2000-02-14 | 2003-06-19 | Erwin Galinski | Use of compatible solutes as inhibitors of the enzymatic decomposition of macromolecular biopolymers |
| DE102004016129A1 (en) * | 2004-03-31 | 2005-10-20 | Bitop Ag | Use of combination of osmolyte from extremophilic microorganism, e.g. (hydroxy)ectoine, and evening primrose oil in cosmetics, topical formulations, medical products and pharmaceuticals for skin care and prophylaxis |
| CN101011335A (en) * | 2006-02-03 | 2007-08-08 | Lvmh研究公司 | Protecting, regenerating composition |
Non-Patent Citations (1)
| Title |
|---|
| 朱道辰，等: "相容性溶质四氢嘧啶及其羟基化衍生物的研究进展", 《中国生物工程杂志》, vol. 31, no. 2, 15 February 2011 (2011-02-15), pages 95 - 101 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104273131A (en) * | 2013-07-01 | 2015-01-14 | 镇江拜因诺生物科技有限公司 | Melon and fruit yield increasing agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100068161A1 (en) | Topical composition for the protection and/or treatment of radiation related skin damages | |
| CA3127175C (en) | Use of topical braf inhibitor compositions for treatment of radiation dermatitis | |
| CN101612278B (en) | Medicine for external application for treating pyogenic type contaminated wounds | |
| EP2389188B1 (en) | Fruit and vegetable-derived compositions | |
| CN113648257A (en) | Whitening and freckle-removing composition and preparation method and application thereof | |
| EP0836476B1 (en) | A COSMETIC COMPOSITION comprising the glycopropyl ester of retinoic acid FOR SKIN APPLICATIONS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF skin diseases, TUMOROUS CELLS, BLADDER OR NERVE DISORDERS | |
| CN102349912A (en) | Medicament for preventing and treating radioactive skin injury | |
| CN101670126A (en) | Fructus forsythiae volatile oil medical hydrocolloid dressing and preparation method thereof | |
| CN106619987A (en) | Externally-applied agent for prevention and treatment of pruritus and eczema at female sensitive position | |
| Davids et al. | A rare repigmentation pattern in a vitiligo patient: a clue to an epidermal stem‐cell reservoir of melanocytes? | |
| CN105687125A (en) | Silica gel for treating skin diseases | |
| CN103933068A (en) | Itching-relieving and antianaphylaxis ointment and preparation method thereof | |
| CN105031254B (en) | A kind of paste and preparation method thereof for treating dermatitis | |
| Spasić et al. | Radiodermatitis-review of treatment options | |
| CN103585334B (en) | Compound diaper ointment | |
| JPH05139983A (en) | Dermatotherapeutic agent | |
| CN106667870A (en) | Facial mask | |
| CA3051652C (en) | Glycopeptide derivatives for use in the treatment and/or prevention and/or attenuation of fibrosis diseases | |
| CA2934118A1 (en) | Cortexolone 17.alpha.-propionate for use in the treatment of skin wounds and/or atrophic skin disorders | |
| CN110393772A (en) | A kind of pharmaceutical composition and preparation method promoting radiotherapy patient skin wound healing | |
| CN110787077A (en) | Body lotion formula for daily maintenance of psoriasis skin | |
| CN110624032A (en) | Ointment for treating burns and scalds and preparation method thereof | |
| CN118490800B (en) | Pharmaceutical composition for clearing heat and relieving itching as well as preparation and application thereof | |
| KR20130077953A (en) | Elastase inhibitors containing carnosic acid or derivatives thereof | |
| CN106491512A (en) | A kind of bio protease new life essence cream |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120215 |